Advent Life Sciences
Advent Life Sciences
We invest predominantly in early and mid-stage life sciences companies. We seek to back truly innovative companies that have a first-in-class or best-in-class approach and who are looking for a well-connected partner on the road to success.
Our investments cover a range of sectors within life sciences, including new drug discovery, enabling technologies, med tech and diagnostics.Advent Life Sciences is one of Europe’s leading venture teams investing in life sciences businesses. We are a deliberately small, and highly focused team of senior individuals, with long-standing track records of entrepreneurial and investment success across the UK, Europe and the USA.
Real people. Real insight. Real value.
Innovation. Clarity. Execution.
AFH Holding & Advisory
Amir Heshmatpour
Founder & Managing DirectorAisling Capital
Dennis Purcell
Founder and Senior AdvisorAlexion
Mark Day
Senior Director Strategic EvaluationAntibody Solutions
Antibody Solutions is a premier developer of therapeutic, diagnostic and critical reagent antibodies. Our platforms include human antibodies from transgenic OmniRats™, Hybridoma Libraries™, and high-throughput flow-cytometry screening of cell-associated targets. We provide full technical support and project management with all services performed in the USA.
John Kenney
PresidentATEM Capital
Alexey Afanasiev
Executive PartnerAnton Gopka
CEO General PartnerElena Ikhsanova
COO General PartnerBaxter Ventures
Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.
Priyanka Rohatgi
DirectorBecton Dickinson (BD)
Albert Lauritano
Director Strategic Technology PartnershipsBiosight, LLC and MIT
Biosight, LLC is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications